After-hours trading on Thursday saw a partial recovery for Ensysce Biosciences, Inc. (NASDAQ: ENSC), reducing the market volatility that had been caused by a major equities release earlier in the day. In the extended session, shares of ENSC increased 7.86% to settle at $2.47 after dropping 13.26% during normal trading hours.
New Capital via Private and Registered Offerings
Ensysce Biosciences said that it had signed definitive agreements to generate around $1.1 million in gross revenue. ENSC will issue and sell 315,188 shares of its ordinary stock at a price of $3.49 per share through a registered direct offering priced at-the-market. In tandem, the company will conduct a private placement involving the issuance of unregistered Series A-5 and Series A-6 warrants, each allowing the purchase of up to 315,188 shares.
At a price of $3.24 per share, the Series A-5 and A-6 warrants will be immediately exercisable. The Series A-6 warrants will be valid for five years, whilst the Series A-5 warrants will be valid for eighteen months. Depending on normal closing circumstances, the offering is anticipated to close on or around March 31, 2025. The offering’s proceeds will be used for general working capital and the advancement of Ensysce Biosciences’ exclusive TAAP and MPAR projects.
PAINWeek 2025 Preparations
As part of its efforts to strengthen its clinical and scientific presence, Ensysce Biosciences announced that on September 3, 2025, at PAINWeek 2025, it would host a symposium. The event’s goal is to further the discussion on pain management and the future of analgesic treatments.
New Developments in Pain Management
As part of the symposium preparations, ENSC recently held a panel discussion titled “The State of the Nation in Pain: A Discussion on Analgesics and Their Optimal Uses.” The panel covered new advances including Ensysce Biosciences’ PF614, a next-generation opioid, as well as the therapeutic value of presently existing analgesics and advancements in pain treatment. ENSC remains committed to collaborating with medical professionals as it creates a new class of pain treatment.
